Bio News
JW Pharmaceutical has applied to South Korea’s Ministry of Food and Drug Safety (MFDS) for approval of a domestic phase 3 clinical trial of the injectable diabetes drug bofanglutide. The trial will enroll 174 patients with type 2 diabetes whose blood glucose is not controlled with combination therapy using metformin and an SGLT-2 inhibitor. Bofanglutide is expected to improve medication convenience by reducing the number of annual doses by half through administration once every 2 weeks.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
